StatLab expands global reach and core manufacturing capabilities with CellPath Ltd. acquisition
MCKINNEY, Texas, June 08, 2022--(BUSINESS WIRE)--StatLab Medical Products (StatLab), an Audax Private Equity and Linden Capital Partners portfolio company and a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has acquired CellPath Ltd. (CellPath), a UK-based manufacturer and supplier of products and services focused on the histology and cytology markets. This addition of new manufacturing capabilities and established UK customer base both strengthens the core business and positions StatLab for international growth and market expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607006320/en/
Based in the UK, CellPath was founded in 1969 by Peter Webber as a histology consumables company known as Bethlehem Instruments, and quickly expanded into equipment. Today, CellPath is an established market leader in Europe, providing key products and services to both the cytology and histology market segments. With this acquisition, StatLab expands its reach into Europe, adds key injection molding manufacturing capabilities, and acquires proprietary products including the CellNass archiving service.
"We have long respected CellPath for their well-earned reputation of delivering innovative products that solve problems for labs, and are proud to welcome them to the StatLab family of brands," said Mike Karsonovich, CEO of StatLab. "Now paired with the strategic acquisition of UK-based equipment manufacturer Pyramid Innovation in 2021, CellPath’s established European market position and complementary portfolio will empower meaningful international growth in the histology sector."
Philip Webber, CellPath Joint Managing Director along with his brother Paul, adds, "StatLab is an excellent fit for us; their US market access and business infrastructure will help jointly expand customer access to products and services as a global market leader. We also appreciate their leadership commitment to ensure we maintain the high levels of service and quality that our family’s business is known for as we partner as one organization."
CellPath will continue operating in the same locations and under the existing leadership structure to prevent any business disruption.
Founded in 1976, StatLab Medical Products is leading the way in development and manufacturing of high-quality histology, cytology and immunohistochemistry diagnostic products. We partner with anatomic pathology laboratories to provide easy access to over 3,500 high-quality diagnostic products and equipment at excellent prices, delivered with expert support. When you work with StatLab, we’re on your team, and you’re part of our family. Learn more at StatLab.com.
CellPath Limited is a UK-based company, specializing in the manufacture and worldwide supply of products, consumables and services to the Cellular Pathology sector. The CellPath name is synonymous with innovative, well-proven products, manufactured to a very high standard. With an in-house state of the art injection molding capability, they manufacture many of the plastic products that are used in the modern Histology and Cytology laboratory, and their ability to sell direct from manufacture to the end user enables cost-saving without compromise on quality and service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006320/en/
Jessica Baer jbaer@statlab.com
Homeowners beware. But don't panic, either.
KEY WORDS “I think we’re giving Powell too much praise. … The last two years are one of the biggest policy mistakes in the 110-year history of the Fed by staying so easy when everything was booming.
On Wednesday, the Fed bumped up interest rates again, its third 75-basis point hike since June, and signaled that there could be two more such hikes by the end of this year. The conventional wisdom has the Fed acting properly, and aggressively, in an attempt to counter inflation raging at 40-year high levels. But conventional wisdom isn’t always right – and we can learn a lot by consulting the contrarians. Few top investors are more contrarian than Cathie Wood. The founder and manager of ARK Inv
And what it means for your wealth-building options.
You have just a few weeks to pounce on Treasury I bonds' sky-high interest rate. Also called Series I savings bonds, their interest rate is 9.62%.
“We printed up too much money, and just thought the party would never end,” Icahn said, adding that with the Fed raising rates to fight inflation, "the party's over."
Yahoo Finance's Julie Hyman discusses Tesla's vehicle recall and latest legal news.
At a companywide all-hands meeting this week, Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) chief Sundar Pichai juggled tough questions from employees regarding cuts to travel and entertainment budgets, managing productivity, and potential layoffs. Employees questioned why Google is "nickel-and-diming employees" by cutting travel and swag budgets despite record profits and substantial cash reserves as it did after the pandemic. Pichai emphasized acting responsibly to tide through such critical sit
AT&T has been crushed this year, down more than 40% from its high. But now the stock nears a key area on the charts with a 7% dividend yield.
The shipping company has developed a reputation as one of the best dividend stocks around
Multiple insiders secured a larger position in Intel Corporation ( NASDAQ:INTC ) shares over the last 12 months. This...
The hedge fund legend has spoken. Pay attention.
Warren Buffett’s long-term investment strategy has proven to be successful through virtually all market conditions over the past several decades – recession, high inflation and deflation. If there’s one thing that’s made Buffett one of the most successful investors in history, it’s his commitment to his strategy. A countless number of new investment techniques and algorithms have come and gone over the years, but Buffett has maintained his relatively simple strategy of picking solid companies an
Forget everything you think you know about the relationship between interest rates and the stock market.
Yahoo Finance reporter Alexandra Semenova breaks down Cathie Wood's decision to hand off her role as portfolio manager on two ETFs.
Yahoo Finance Live anchor Seana Smith highlights stocks moving in after-hours trading, including Ford, FedEx, and Moderna.
Crypto markets are down sharply after Fed Chair Jerome Powell and JPMorgan CEO Jamie Dimon both voiced regulatory concerns earlier this week.
As much as stocks are falling, moves in another financial market have even more profound implications for the global economy.
It's Friday morning -- two days after the Federal Reserve raised interest rates 0.75%, and one day after seemingly every other central bank in the world followed suit, according to The Wall Street Journal -- and oil stocks are tanking. As of 9:50 a.m. ET, shares of oil company Occidental Petroleum (NYSE: OXY) are down 5.6%, while industry bellwether ExxonMobil (NYSE: XOM) is down a solid 6%, and refiner Phillips 66 (NYSE: PSX) is leading the pack lower with a 6.7% loss.
Boise, Idaho; Philadelphia; Pensacola, Fla.; Austin; and Reno, Nev.; Minnesota; and Utah are the housing markets with the most buyer pullback, says one home builder.